Skip to main content

Peer Review reports

From: Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study

Original Submission
2 Aug 2023 Submitted Original manuscript
24 Aug 2023 Author responded Author comments - Lin Wu
2 Sep 2023 Reviewed Reviewer Report
8 Sep 2023 Reviewed Reviewer Report - Kenji Morimoto
20 Sep 2023 Author responded Author comments - Lin Wu
Resubmission - Version 2
24 Aug 2023 Submitted Manuscript version 2
Publishing
29 Sep 2023 Editorially accepted
16 Oct 2023 Article published 10.1186/s12885-023-11465-2

You can find further information about peer review here.

Back to article page